| 2017-05 |
A phase I dose escalation study of SCBO1A, a micro tubular inhibitor with vascular disrupting activity, in patients with advanced solid tumors refractory to standard therapy |
Journal of Clinical Oncology. 2017 May;35(Suppl. 15):Meeting Abstract 2531. |
|
| 2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745. |
 |
| 2013-05 |
Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 10619. |
|
| 2013-01 |
Randomised clinical trial: Comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma |
Alimentary Pharmacology and Therapeutics. 2013 Jan;37(1):62-73. |
|
| 2012-09 |
Early data from a phase I study of nintedanib (BIBF1120) in Asian patients with advanced hepatocellular carcinoma |
Annals of Oncology. 2012 Sep;23(Suppl. 9):246-247. |
|
| 2012-02 |
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy |
Journal of Clinical Oncology. 2012 Feb;30(4):613. |
|
| 2011-12-15 |
Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors |
Free Radical Biology and Medicine. 2011 Dec 15;51(12):2195-2209. |
|
| 2011-10 |
Novel feedback inhibition of surface antigen synthesis by Mammalian Target of Rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy |
Hepatology. 2011 Oct;54(4):1199-1207. |
|
| 2011-04 |
Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas |
Cancer Research. 2011 Apr;71:Abstract number 1701. |
|
| 2011-02 |
Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma |
Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4):Abstract Number 79. |
|
| 2010-06 |
Randomized, phase 1 study of everolimus in patients with advanced hepatocellular carcinoma |
Annals of Oncology. 2010 Jun;21(Suppl. 6):27. |
|
| 2009-12 |
Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent |
Journal of Clinical Oncology. 2009 Dec;27(36):e271. |
|
| 2009-11 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer |
Cancer Chemotherapy and Pharmacology. 2009 Nov;64(6):1173-1179. |
|
| 2009-09 |
Synergistic augmentation of arsenic trioxide-induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors |
EJC Supplements. 2009 Sep;7(3):16. |
|
| 2009-05-20 |
Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC) |
Journal of Clinical Oncology. 2009 May 20;27(15s):Abstract number 4587. |
|
| 2007-11-15 |
Tamoxifen accelerates proteasomal degradation of O-6-methylguanine DNA methyltransferase in human cancer cells |
International Journal of Cancer. 2007 Nov;121(10):2293-2300. |
|
| 2007-03-01 |
Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036 |
Biochemical Pharmacology. 2007 Mar;73(5):610-619. |
|
| 2007-01 |
D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation |
Molecular Cancer Therapeutics. 2007 Jan;6(1):193-202. |
|
| 2006-11 |
Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma |
Cancer Chemotherapy and Pharmacology. 2006 Nov;58(5):654-664. |
|
| 2006-11 |
D-501036, a novel selenophene-base triheterocycle derivative exhibits potent in vitro and in vivo anti-tumoral activity, which involves DNA-damage and ATM activation |
EJC Supplements. 2006 Nov;4(12):92. |
|
| 2006-10 |
Inhibition of cell growth and nuclear factor-kappa B activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503 |
Molecular Cancer Therapeutics. 2006 Oct;5(10):2484-2493. |
|
| 2006-10 |
Abrogation of skin disease in lupus-prone MRL/Fas(lpr) mice by means of a novel tylophorine analog |
Arthritis and Rheumatism. 2006 Oct;54(10):3277-3283. |
|
| 2006-05 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer |
Journal of Gastroenterology and Hepatology. 2006 May;21(5):874-879. |
|
| 2006-03 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer |
Journal of Gastroenterology and Hepatology. 2006 Mar;21(3):531-536. |
|
| 2005-12 |
Pulmonary embolism after transcatheter arterial chemoembolization |
European Journal of Cancer Care. 2005 Dec;14(5):440-442. |
|
